BMO Capital Remains a Buy on Aptinyx (APTX)

In a report released today, Gary Nachman from BMO Capital maintained a Buy rating on Aptinyx (APTXResearch Report), with a price target of $2.00. The company’s shares opened today at $0.31.

Nachman covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Horizon Therapeutics, and AbbVie. According to TipRanks, Nachman has an average return of -9.1% and a 40.76% success rate on recommended stocks.

Currently, the analyst consensus on Aptinyx is a Moderate Buy with an average price target of $1.67.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $3.76 and a one-year low of $0.20. Currently, Aptinyx has an average volume of 421.4K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aptinyx Inc. is a clinical stage biopharmaceutical company. It engages in the discovery, development, and and commercialization of transformative therapies for disorders of the brain and nervous system. Its product includes NYX-2925, NYX-783, NYX-458, and the AGN-241751 program. The company was founded by Norbert G. Riedel and Joseph R. Moskal in June 2015 and is headquartered in Evanston, IL.

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More